Clinical Trial Investigating Pazopanib in Patients With Platinum-resistant Advanced Ovarian Cancer
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Given the low Responses Rates and short survival times achieved with conventional cytotoxic
agents in resistant ovarian cancer patients, new treatment options are needed in this patient
population.Antiangiogenic therapy has an important role in this group of patients and
Pazopanib in particular. We are going to study if Pazopanib is able to control
disease-related symptoms minimizing the side effects of treatment. This aspect is very
important in the treatment of resistant ovarian cancer patient since our treatment is
palliative without any impact in overall survival. So our goal is to study the Clinical
Benefit Rate (objective responses plus stable disease rates) achieved with Pazopanib and its
toxicity profile in this subgroup of patients
Phase:
Phase 2
Details
Lead Sponsor:
Grupo Español de Investigación en Cáncer de Ovario